Use of Injectable Platelet Rich Fibrin in Lichen Planus
Launched by BEZMIALEM VAKIF UNIVERSITY · Aug 25, 2017
Trial Information
Current as of August 29, 2025
Completed
Keywords
ClinConnect Summary
Lichen planus diagnosis will be made histopathologically. Intraoral photographs and measurements will be taken at the beginning of the treatment and 2 months after the treatment is finished.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Oral erosive lesions were diagnosed according to Andreasen classification.
- • 2. Histological confirmation of erosive OLP according to the World Health Organization's clinicopathological diagnostic criteria for OLP.
- • 3. No previous treatment of oral lichen planus at least 3 months.
- • 4. Willingness and ability to complete the present clinical trial.
- • 5. Patients of ages above 18 years old without skin involvement.
- Exclusion Criteria:
- • 1. Histological signs of dysplasia.
- • 2. Using drugs associated with lichenoid reaction.
- • 3. Pregnant, lactating and smoker patients.
- • 4. Patient with systemic diseases such as diabetes mellitus, immunodysfunction, hematological and hepatological patients or had photosensitivity history.
About Bezmialem Vakif University
Bezmialem Vakif University is a prominent academic institution based in Istanbul, Turkey, dedicated to advancing medical research and education. As a clinical trial sponsor, the university leverages its state-of-the-art facilities and a multidisciplinary team of experts to conduct innovative research that aims to improve patient outcomes and enhance therapeutic strategies. Bezmialem Vakif University is committed to adhering to rigorous ethical standards and regulatory guidelines, ensuring the integrity and reliability of its clinical trials while fostering collaboration with global research communities. Through its initiatives, the university seeks to contribute significantly to the field of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
İstanbul, Eyalet/Yerleşke, Turkey
İstanbul, , Turkey
Patients applied
Trial Officials
Ebru Sağlam, PhD
Study Chair
Bezmialem Vakif University
Mustafa Tunalı, Assoc. prof.
Study Director
Bezmialem VakifUniversity
Tuğba Ünver, PhD
Principal Investigator
Bezmialem Vakif University
Zeliha Betül Özsağır
Principal Investigator
Bezmialem Vakif University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials